CN101632404A - Blood sugar reducing healthy tea and preparation method thereof - Google Patents
Blood sugar reducing healthy tea and preparation method thereof Download PDFInfo
- Publication number
- CN101632404A CN101632404A CN200910157342A CN200910157342A CN101632404A CN 101632404 A CN101632404 A CN 101632404A CN 200910157342 A CN200910157342 A CN 200910157342A CN 200910157342 A CN200910157342 A CN 200910157342A CN 101632404 A CN101632404 A CN 101632404A
- Authority
- CN
- China
- Prior art keywords
- parts
- blood sugar
- group
- tea
- raw material
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention relates to blood sugar reducing healthy tea and a preparation method thereof. The blood sugar reducing healthy tea is prepared by the following steps: using guayaba leaves, cassia bark, momordica grosvenori and jasmine tea as raw materials; cleaning and removing impurities and rotten bad raw materials, drying at 50-85 DEG C and crushing, sieving by a vibration sieve; taking 20-60mu of raw materials, mixing according to the proportion, sterilizing and packaging. The invention has the advantages of special formulation, accurate treatment effect, convenient use, low cost and safety without toxic and side effects, has the functions of clearing heat and enriching the saliva, tonifying spleen and resolving dampness, and reducing blood sugar and lipid, and is suitable to patients with abnormal glucose tolerance and mild diabetes mellitus. Tests show that the invention has the functions of reducing blood sugar, lightening insulin resistance, increasing the sensitivity of insulin, protecting the function of Beta cells, and lowering serum total cholesterin and serum triglyceride without toxic and side effects.
Description
One, technical field
The present invention relates to a kind of antihypelipidemic health tea and preparation method thereof.
Two, background technology
IGT (IGT) is meant patient's a kind of intermediateness of blood sugar between normal person's blood glucose value and glycosuria patient blood glucose value.It is generally accepted that at present IGT is the early stage of diabetes, is a distress phase that develops into diabetes.Along with the raising of people's living standard, the illness rate of IGT obviously increases.WHO announces that in 1993 30～64 years old adult IGT illness rate in the whole world mostly is 3.0%～10.0% greatly.National Diabetes Epidemiological Investigation IGT markization illness rate was the highest by 5.78% with provincial capital in 1996, and minimum is poor counties and townships 3.14%.China has 1,300,000,000 populations now, if the IGT illness rate is calculated by average 4.46%, then number of patients will be more than 5,798 ten thousand, be higher than the number of patients (3,000 ten thousand) of China's diabetes far away.Studies show that had 1/3 IGT to change diabetes into approximately in per 5～10 years, 1/3 changes into normally, and 1/3 still keeps IGT.Develop into Non-Insulin Dependent Diabetes Mellitus (NIDDM) person every year and be about 1%～5%, the accumulation illness rate can be up to 40%.The year ratio that 30～64 years old IGT of capital, Beijing iron and steel parent company transfers NIDDM to is 8.95%.This shows that though China IGT illness rate is lower than external physical data, wherein the incidence of disease of diabetes is high abroad.Calculate simply that from above-mentioned data China every year, this was the problem of a significant and research by the patient who develops into diabetes among the IGT patient who makes a definite diagnosis 150～1,800,000 nearly.
Therapeutic intervention to IGT mainly is behavior intervention and pharmaceutical intervention at present, and the behavior intervention treatment comprises adjustment life style: rational meals and increase amount of exercise.Majority thinks that the behavior intervention that IGT patient is carried out diet and exercise therapy is the effective measures that reduce the diabetes incidence, but still has suitable patient's state of an illness to continue progress.Though the chemical medicine of existing treatment diabetes such as sulfonylurea drugs, insulin sensitizer, melbine, alpha-glucosidase inhibitor etc. can be used for treating IGT, very easily cause hypoglycemia, general patient is difficult to bear.According to clinical investigation, in the IGT stage, Most patients does not accept to use the chemicals treatment, and is ready to accept the Chinese medicine conditioning.For this reason, the present invention is guidance with the theory of traditional Chinese medical science, on the basis of clinical experience for many years, adopting medicinal and edible Chinese medicine is the health protection tea of main development treatment IGT, show through clinical practice, pharmaceutical composition of the present invention has no side effect to IGT and slight diabetic's determined curative effect, has the effect that reduces blood sugar, reducing blood lipid, alleviates insulin resistance.
Three, summary of the invention
The object of the present invention is to provide the health protection tea and preparation method thereof of the treatment IGT of a kind of determined curative effect, no obvious toxic-side effects, be applicable to IGT and slight diabetic.
Technical scheme of the present invention: a kind of antihypelipidemic health tea and preparation method thereof is characterized in that being prepared from by following raw material composition and weight proportion: 5～40 parts of Guava Leafs, 1～10 part of Chinese cassia tree, 0.5～8 part of Momordica grosvenori, 0.5～8 part of jasmine tea; Preferred weight ratio range of the present invention is: 10～25 parts of Guava Leafs, 2～8 parts of Chinese cassia trees, 1～5 part of Momordica grosvenori, 1～5 part of jasmine tea; Optimum weight ratio range of the present invention is: 19 parts of Guava Leafs, 5 parts of Chinese cassia trees, 3 parts of Momordica grosvenoris, 3 parts of jasmine teas.
The preparation method of a kind of antihypelipidemic health tea and preparation method thereof, it is characterized in that above raw material respectively through selected, remove impurity and go rotten rotten raw material, oven dry, pulverizing, behind the reciprocating sieve sub-sieve, get 20～60 order raw materials, mix in proportion, sterilize, pack and form; Wherein baking temperature is at 50～85 ℃; Sterilization method is cobalt 60 radiation sterilizations, microwave sterilization or pressure sterilizing; Every bag of specification 2～5 grams.
The invention has the advantages that the prescription uniqueness, determined curative effect, easy to use, economy, safe without toxic side effect have the dispel effect of fat of clearing heat and promoting fluid, invigorating the spleen for eliminating dampness, hypoglycemic, are applicable to IGT and slight diabetic.Experimental study shows that the present invention has the blood sugar of reduction, alleviates insulin resistance, increases the sensitiveness of insulin, and protection β cell function reduces serum total cholesterol and serum levels of triglyceride, does not see toxic and side effect.Mainly clinical, pharmacodynamics and toxicology test result of study are as follows:
Test example one: thing of the present invention is to IGT patient's clinical efficacy
1, object and method: (1) diagnostic criteria (reference " Chinese treating diabetes guide " 2004): sugar tolerance impaired (IGT): fasting blood-glucose (FPG) value＜7.0mmol/L (126mg/dl), and 2 o'clock blood sugar (the 2HPG) 〉=7.8mmol/L (140mg/dl) in load back,＜11.1mmol/L (200mg/dl).(2) include the case standard in: Western medicine diagnose is the IGT person, and the age is between 40～65 years old.Accept 70 routine IGT patients altogether for medical treatment, be divided into 2 groups at random, i.e. 35 examples are organized in control group 35 examples, treatment.Control group: give and behavior intervention, promptly diet adds motion; The treatment group: give with behavior intervention to add thing treatment of the present invention, i.e. diet, motion adds thing of the present invention and (made every bag of 3g by Guava Leaf, Chinese cassia tree, Momordica grosvenori, jasmine tea for each 1 bag.), every day 3 times, 2 months is a course of treatment.(5) MAIN OUTCOME MEASURES: fasting blood-glucose (FPG), 2 hours after the meal blood sugar (2hPG), glycosylated hemoglobin (HbA
1C), plasma insulin (FINS).70 routine patients lose and visit 5 examples when finishing to the observation period, control group 4 examples wherein, and 1 example is organized in treatment.
2, efficacy evaluation: (1) control: 2 o'clock blood sugar in carbohydrate tolerance test clothes sugar back and fasting blood-glucose all recover normal; (2) effective: 2 o'clock blood sugar in carbohydrate tolerance test clothes sugar back or fasting blood-glucose reduce, but recover normal; (3) invalid: 2 o'clock blood sugar in carbohydrate tolerance test clothes sugar back and fasting blood-glucose do not have and improve or raise.
3, clinical observation result
(1) treatment front and back two groups of FPG, 2hPG, HbA
1c, FINS comparison
Two groups of FPG, 2hPG, HbA after table 1 treatment February
1c, FINS comparison (x ± s)
Annotate: self compare P＜0.05 before and after the △ treatment.▲ compare P＜0.05 with control group.
By table 1 as seen, treat after 2 months, control group FPG, 2hPG have decline before intervening, but do not have significant difference (p＞0.05); Control group HbA
1There is not difference before and after C and the FINS treatment.Significant difference (p＜0.05) before and after treatment group FPG, the 2hPG treatment also has significant difference (p＜0.05) with control group comparison FPG, 2hPG.Illustrate that thing of the present invention has the effect that reduces empty stomach and postprandial hyperglycemia preferably; Significant difference result (p＜0.05) before and after the treatment group FPI horizontal stretcher shows that thing of the present invention has the effect of the insulin sensitivity of raising.
Test example two, thing of the present invention are to the influence of spontaneous diabetes B KKAy mouse
1, materials and methods
1.1 material
1.1.1 medicine: thing of the present invention is made by Guava Leaf, Chinese cassia tree, Momordica grosvenori, jasmine tea, every bag of 3g.Brewed 15 minutes with boiling water before the experiment, make every milliliter and contain the 2g crude drug.Distilled water is mixed with low, the high two kinds of concentration solution of 0.08g/ml, 0.32g/ml.4 ℃ of preservations, seven days shelf-lifves.Take out soup before irritating the stomach prerequisite, use after being placed to normal temperature.
Auspicious red (PIOGITAZONE HYDROCHLORIDE sheet) 15mg/ sheet, authentication code: the accurate word H20040631 of traditional Chinese medicines, made by Hengrui Medicine Co., Ltd., Jiangsu Prov..Take out tablet during experiment and be ground into fine powder, be mixed with the solution of desired concn 0.10mg/ml with distilled water.4 ℃ of preservations, three days shelf-lifves.Take out soup before irritating the stomach prerequisite, use after being placed to normal temperature.
1.1.2 animal: 45 of the healthy male KKAy mouse of 8～12 SPF levels in age in week, 10 of the healthy male C57bl/6J mouse of 8～12 SPF levels in age in week provide by Institute of Experimental Animals, Chinese Academy of Medical Sciences.
1.2 method
1.2.1 feed formula
The KKAy mouse is fed full price high lipid food (available from Institute of Experimental Animals, Chinese Academy of Medical Sciences, forming: 78.8% basal feed, 1% cholesterol, 10% yolk powder, 10% lard, 0.2% cholate); The C57bl/6J mouse is fed the full nutrition pellet.
1.2.2 the affirmation of model
After adaptability is fed a week, the hematometry random blood sugar is got in 45 dockings of the healthy male KKAy mouse of SPF level, twice random blood sugar all can be used for this test the above person of 13.9mmol/L.
1.2.3 grouping
Qualified KKAy mouse amounts to 40, looks into table of random number by the random blood sugar value and is divided into 4 groups at random, 10 every group: each 10 of model group, high dose group, low dose group and positive controls (Pioglitazone); Other establishes 10 of the healthy male C57bl/6J mouse of SPF level and is the normal control group.
1.2.4 medication
The normal control group: gavage sterilized water by 20ml/kg/d, once a day, continuous 8 weeks.Model group: gavage sterilized water by 20ml/kg/d, once a day, continuous 8 weeks.The administration group: the high and low dose group is respectively with 1.6g/kg, and 0.4g/kg gavages and is subjected to the reagent thing, once a day, and continuous 8 weeks.Positive controls: gavage by 1.95mg/kg/d, once a day, continuous 8 weeks.
1.2.5 sample preparations
Each is organized mouse and raised for 8 weeks, and the socket of the eye vein is got blood behind the fasting water 12h, leaves standstill 4 ℃ of 1500 commentaries on classics separation of serum after 2～3 hours ,-20 ℃ of preservations.
1.3 observation index and detection method
1.3.1 the growth of animal situation is observed:
Experimental session is observed animal spirit, activity, hair color, feed, drinking-water and urine quantitative changeization, and writes down body weight weekly.
1.3.2 fasting blood-glucose concentration determination (FPG): measure fasting blood-glucose with blood glucose meter (German Luo Kang is complete).
1.3.3 serum insulin level is measured (Fins) on an empty stomach: radio immunoassay is measured serum insulin level (Fins) on an empty stomach.
1.3.4 insulin action index (IAI): adopt China-Japan Friendship Hospital's Guangwei LI teaching methods, IAI=1/FPG * FINS, this value is Non-Gaussian Distribution, so get its natural logrithm during calculating.
1.3.5 four mensuration of blood fat: automatic clinical chemistry analyzer is measured four of blood fat.
1.3.6 free fatty (FFA): copper colorimetric method for determining free fatty (FFA).
(x ± s) expression uses SPSS 11.5 software analysis 1.4 the statistical method experimental data is with mean ± standard deviation.Conspicuousness relatively adopts one-way analysis of variance (oneway ANOVA) between each group.When P＜0.05, be considered to statistical significance.
2 results
2.1 ordinary circumstance
The normal control group C57bl/6J mouse state of mind is good, is quick on the draw, and moves freely, and fur is glossy, and body weight rises continually and steadily.Model group KKAy mouse is One's spirits are drooping, slow in reacting along with the growth in age in week engenders, slow movement, and fur tarnishes, and food-intake, the water yield all increase to some extent, and the urine amount increases obviously.Chinese medicine high low dose group treatment group and Pioglitazone treatment group have the performance of close copy group, but degree is lighter.
2.2 thing of the present invention is to the influence of spontaneous diabetes B KKAy mouse fasting blood-glucose
Respectively organize relatively (x ± s) of mouse FPG, Fins, IAI level after table 2 treatment
Annotate: compare △ P＜0.01 with normal group; Compare with model group,
*P＜0.05,
*P＞0.01; Compare #P＞0.05 with the Pioglitazone group.
As known from Table 2: (1) model group mouse FPG raises, and compares with normal group, has significant difference (P＜0.01); Object height dosage group of the present invention and Pioglitazone group are improved all obvious to FPG, compare with model group, and difference has conspicuousness (P＜0.05); Object height of the present invention, low dose group and model group compare, and difference has conspicuousness (P＜0.05); Object height dosage group of the present invention and Pioglitazone group relatively do not have significant difference (P＞0.05).(2) model group mouse Fins obviously raises, and compares with normal group, has significant difference (P＜0.01); Object height of the present invention, low dose group, three groups of Fins of Pioglitazone group all descend, and compare with model group, and difference has conspicuousness (P＜0.01); Object height dosage group of the present invention and Pioglitazone group relatively do not have significant difference (P＞0.05), and thing low dose group of the present invention and Pioglitazone group relatively have significant difference (P＜0.05).(3) model group mouse IAI obviously descends, and compares with normal group, has significant difference (P＜0.01); Object height of the present invention, low dose group, three groups of IAI of Pioglitazone group all raise, and compare with model group, and difference has conspicuousness (P＜0.05); Object height dosage group of the present invention and Pioglitazone group relatively do not have significant difference (P＞0.05).
2.3 thing of the present invention is to the influence of spontaneous diabetes B KKAy mouse blood lipid level
Respectively organize relatively (x ± s) of mouse blood lipid level after table 3 treatment
Annotate: compare △ P＜0.05 with normal group; Compare with model group,
*P＞0.05
As known from Table 3, model group mouse TC, TG, LDL-C all obviously raise, and HDL-C obviously reduces, and compare with normal group, have significant difference (P＜0.05); There are no significant (P＞0.05) than difference with model group for each group of administration, but downward trend is arranged.
2.4 thing of the present invention is to the influence of spontaneous diabetes B KKAy mouse FFA level
Respectively organize relatively (x ± s) of mouse FFA level after table 4 treatment
Annotate: compare △ P＜0.01 with normal group; Compare with model group,
*P＜0.05,
*P＜0.01.
As known from Table 4, model group mouse FFA obviously raises, and compares with normal group, has significant difference (P＜0.01); The Pioglitazone group is improved obviously FFA, compares with model group, and difference has conspicuousness (P＜0.01); Object height dosage group of the present invention is compared difference with low dose group with model group have conspicuousness (P＜0.01).
It is that research object is observed the intervention effect of thing of the present invention to the diabetes B insulin resistance that spontaneous diabetes B KKAy mouse model is selected in this research.The KKAy mouse is a kind of hair color gene A y saltant diabetic mice, the Ay gene not only influences the hair color of mouse but also can cause that the unusual syndromes of metabolism such as obesity, hyperglycaemia, disorders of lipid metabolism and hyperinsulinemia appear in metabolic disorder, its morbidity is to add environmental factor and bring out on the basis of inheritance susceptible, very similar to human diabetes B performance, be a kind of desirable people's type diabetes animal model, be the typical model of insulin resistance.
There are some researches show that FFA raises can directly cause IR, accounts for critical role in the generation of diabetes B and development.Not controlling diabetes patient's serum FFA level can be up to 1.5mmol/L.Under the normal condition, high density F FA stimulates insulin secretion, and conversely, insulin secretion inhibitory hormone sensitive lipase is active and reduce the periphery lipolysis.The diabetes B patient is then because peripheral insulin resistance, the lipotropism effect of separating of insulin descended cause FFA to raise and hyperinsulinemia.A large amount of evidences show that the insulin resistance of diabetes B no matter or IGT and normal pregnancy all increases relevant with FFA.Therefore, in the research to diabetes B and IR, the effect of FFA in morbidity and disease progression is one of focus of research all the time at present.
This experimental result shows that model group KKAy mouse produces obvious insulin resistance, shows as fasting blood-glucose serum insulin level, blood fat, FFA, TNF-α and obviously increases, and IAI reduces.Thing of the present invention does not have obvious influence to the every index of non-diabetic C57BL/6J mouse.After thing of the present invention treated for 8 weeks, the fasting blood-glucose of KKAy mouse, all obviously improvement of serum insulin level, insulin resistance index, FFA on an empty stomach.Blood fat has reduction trend, may be short relevant with treatment time, and its mechanism remains further to be explored.The result shows that thing of the present invention can effectively improve the depletion that the plain resistance state of spontaneous diabetes B KKAy mouse islets also can delay the β cell to a certain extent, plays a protective role.Infer that its mechanism may be by acting on the acceptor metasomite, the level of regulation and control free fatty and working.
Four, the specific embodiment
With specific embodiment the present invention is elaborated below:
Embodiment 1:
Take by weighing raw material according to following proportioning: 28 parts of Guava Leafs, 8 parts of Chinese cassia trees, 6 parts of Momordica grosvenoris, 5 parts of jasmine teas.
The preparation method: above raw material respectively through selected, remove impurity and the rotten raw material that goes rotten, 70 ℃ of oven dry, pulverizing, behind the reciprocating sieve sub-sieve, get 30 order raw materials, mix in proportion, sterilize, pack and form; Wherein sterilization method is cobalt 60 radiation sterilizations, microwave sterilization or pressure sterilizing; Every bag of specification 2～5 grams.
Embodiment 2:
Take by weighing raw material according to following proportioning: 5 parts of Guava Leafs, 2 parts of Chinese cassia trees, 1 part of Momordica grosvenori, 1 part of jasmine tea.
The preparation method: above raw material respectively through selected, remove impurity and the rotten raw material that goes rotten, 80 ℃ of oven dry, pulverizing, behind the reciprocating sieve sub-sieve, get 40 order raw materials, mix in proportion, sterilize, pack and form; Wherein sterilization method is cobalt 60 radiation sterilizations, microwave sterilization or pressure sterilizing; Every bag of specification 2～5 grams.
Embodiment 3:
Take by weighing raw material according to following proportioning: 19 parts of Guava Leafs, 5 parts of Chinese cassia trees, 3 parts of Momordica grosvenoris, 3 parts of jasmine teas.
The preparation method: above raw material respectively through selected, remove impurity and the rotten raw material that goes rotten, 50 ℃ of oven dry, pulverizing, behind the reciprocating sieve sub-sieve, get 60 order raw materials, mix in proportion, sterilize, pack and form; Wherein sterilization method is cobalt 60 radiation sterilizations, microwave sterilization or pressure sterilizing; Every bag of specification 2～5 grams.
Embodiment 4:
Take by weighing raw material according to following proportioning: 19 parts of Guava Leafs, 5 parts of Chinese cassia trees, 3 parts of Momordica grosvenoris, 3 parts of jasmine teas.
The preparation method: above raw material respectively through selected, remove impurity and the rotten raw material that goes rotten, 70 ℃ of oven dry, pulverizing, behind the reciprocating sieve sub-sieve, get 35 order raw materials, mix in proportion, sterilize, pack and form; Wherein sterilization method is cobalt 60 radiation sterilizations, microwave sterilization or pressure sterilizing; Every bag of specification 2～5 grams.
Claims (5)
1, a kind of antihypelipidemic health tea is characterized in that being prepared from by following raw material composition and weight proportion: 5～40 parts of Guava Leafs, 1～10 part of Chinese cassia tree, 0.5～8 part of Momordica grosvenori, 0.5～8 part of jasmine tea.
2, as claims 1 described a kind of antihypelipidemic health tea, its raw material and weight proportion are: 10～25 parts of Guava Leafs, 2～8 parts of Chinese cassia trees, 1～5 part of Momordica grosvenori, 1～5 part of jasmine tea.
3, as claims 1 described a kind of antihypelipidemic health tea, its raw material and weight proportion are: 19 parts of Guava Leafs, 5 parts of Chinese cassia trees, 3 parts of Momordica grosvenoris, 3 parts of jasmine teas.
4, as the preparation method of claims 1～3 described a kind of antihypelipidemic health tea, it is characterized in that: above raw material respectively through selected, remove impurity and the rotten raw material that goes rotten, 50～85 ℃ of oven dry, pulverizing, behind the reciprocating sieve sub-sieve, get 20～60 order raw materials, mix in proportion, sterilize, pack and form.
5, as the preparation method of claims 4 described a kind of antihypelipidemic health teas, it is characterized in that: sterilization method is cobalt 60 radiation sterilizations, microwave sterilization or pressure sterilizing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910157342A CN101632404A (en) | 2009-07-27 | 2009-07-27 | Blood sugar reducing healthy tea and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910157342A CN101632404A (en) | 2009-07-27 | 2009-07-27 | Blood sugar reducing healthy tea and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101632404A true CN101632404A (en) | 2010-01-27 |
Family
ID=41591872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200910157342A Pending CN101632404A (en) | 2009-07-27 | 2009-07-27 | Blood sugar reducing healthy tea and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101632404A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102217686A (en) * | 2011-06-02 | 2011-10-19 | 王乃利 | Hypoglycemic tea and preparation method thereof |
| CN102696815A (en) * | 2012-04-20 | 2012-10-03 | 江门市江海区南粤金石榴茶制品厂 | Preparation method of guava green tea |
| CN102961446A (en) * | 2012-12-18 | 2013-03-13 | 成都通灵中药饮片精选有限公司 | Guava infused-bag type traditional Chinese tablet with effect of reducing blood sugar and processing method thereof |
| CN103445261A (en) * | 2013-09-12 | 2013-12-18 | 黄昌柏 | Process method for preparing beverage, health-care water, granules and feed by using eastern bracken fern rhizomes |
| CN114190459A (en) * | 2021-12-21 | 2022-03-18 | 昆明理工大学 | Auxiliary blood sugar-reducing tea bag and preparation method thereof |
-
2009
- 2009-07-27 CN CN200910157342A patent/CN101632404A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102217686A (en) * | 2011-06-02 | 2011-10-19 | 王乃利 | Hypoglycemic tea and preparation method thereof |
| CN102696815A (en) * | 2012-04-20 | 2012-10-03 | 江门市江海区南粤金石榴茶制品厂 | Preparation method of guava green tea |
| CN102961446A (en) * | 2012-12-18 | 2013-03-13 | 成都通灵中药饮片精选有限公司 | Guava infused-bag type traditional Chinese tablet with effect of reducing blood sugar and processing method thereof |
| CN103445261A (en) * | 2013-09-12 | 2013-12-18 | 黄昌柏 | Process method for preparing beverage, health-care water, granules and feed by using eastern bracken fern rhizomes |
| CN114190459A (en) * | 2021-12-21 | 2022-03-18 | 昆明理工大学 | Auxiliary blood sugar-reducing tea bag and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7069490B2 (en) | Yuricoma longifolia extract and its use in enhancing and / or stimulating the immune system | |
| CN102551065B (en) | Blood sugar reducing food series | |
| CN101632404A (en) | Blood sugar reducing healthy tea and preparation method thereof | |
| CN108271892A (en) | A kind of hypoglycemic health food and preparation method thereof | |
| CN102526479A (en) | Health-care medicine formula with functions of enhancing immunity and lowering blood sugar | |
| CN102935116A (en) | Pharmaceutical compositions or health care product having blood sugar reduction effect | |
| CN103405655B (en) | Chinese medicine composition of a kind of blood sugar lowering and preparation method thereof | |
| CN101606978B (en) | Blood-sugar reducing tea and preparation method thereof | |
| CN101716229A (en) | Health-care tea for regulating blood sugar level and preparation method thereof | |
| CN102366497B (en) | Medicinal compound preparation for treating diabetes and preparation method of medicinal compound preparation | |
| Parsaeyan et al. | Effect of chromium supplementation on blood glucose, hemoglobin A1c, lipid profile and lipid peroxidation in type 2 diabetic patients | |
| CN103550281A (en) | Medicine composition for preventing and treating diabetes and diabetes complications and preparation thereof | |
| CN101204466B (en) | Novel antidiabetic | |
| CN109045070A (en) | A kind of composition for preventing and treating non-alcoholic fatty liver disease | |
| CN108403818A (en) | A kind of composition of auxiliary hyperglycemic and application thereof | |
| CN103989835A (en) | Composition for reducing blood sugar, decreasing blood fat and protecting liver and preparation method and application thereof | |
| CN104958309A (en) | Application of rutin in preparation of drug used for treating obesity and related diseases | |
| CN101879190A (en) | Composition containing curcumin and application of curcumin in preparing composition for adjusting blood sugar | |
| CN102526198A (en) | Medicine with cinnamon and chromium as additives and preparation method for health care product | |
| CN102578451A (en) | Health-care food composite capable of decreasing blood sugar | |
| CN101053592B (en) | Medicinal composition for treating impaired glucose tolerance and preparation method thereof | |
| CN101406642A (en) | Antihypelipidemic compound formulation | |
| CN109999094A (en) | A kind of Chinese medicine tea bag for treating hyperlipidemia | |
| CN109966283A (en) | Application of the degreasing cinnamon polyphenol extract in preparation prevention and treatment diabetic nephropathy product | |
| CN104000865B (en) | It is a kind of that there is reducing blood lipid, the Taurine of function of blood sugar reduction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20100127 |